The impact of liraglutide on diabetes-related foot ulceration and associated complications in patients with type 2 diabetes at high risk for cardiovascular events: Results from the LEADER trial | diabetes.medicinematters.com

Medicine Matters Diabetes

JAVASCRIPT NEEDED

Please enable JavaScript on your browser, so that you can use all features of this website.

window.dataLayer = window.dataLayer || []; window.dataLayer.push({ 'event': 'track', 'eventCategory': 'flash_warning', 'eventAction': 'Javascript needed', 'eventLabel': 'Please enable JavaScript on your browser, so that you can use all features of this website.' });

Top

08-02-2018 | Diabetic foot | Article

The impact of liraglutide on diabetes-related foot ulceration and associated complications in patients with type 2 diabetes at high risk for cardiovascular events: Results from the LEADER trial

Dhatariya K et al. Diabetes Care 2018: dc181094. doi: 10.2337/dc18-1094

Please follow the link below to view this article in full on a third-party website. Note that a subscription or payment may be required.

https://doi.org/10.2337/dc18-1094

Version: 0.1954.0

Medicine Matters Diabetes

The impact of liraglutide on diabetes-related foot ulceration and associated complications in patients with type 2 diabetes at high risk for cardiovascular events: Results from the LEADER trial

New additions to the Adis Journal Club

The challenge of type 2 diabetes in children

Supporting people with diabetes during Ramadan